CSS LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-5,200
Closed -$456K 943
2020
Q4
$456K Hold
5,200
0.02% 483
2020
Q3
$395K Buy
+5,200
New +$526K 0.02% 459
2018
Q4
Sell
-7,700
Closed -$747K 537
2018
Q3
$747K Sell
7,700
-2,900
-27% -$289K 0.03% 259
2018
Q2
$999K Buy
10,600
+2,100
+25% +$184K 0.05% 208
2018
Q1
$689K Sell
8,500
-5,500
-39% -$472K 0.03% 267
2017
Q4
$1.25M Hold
14,000
0.06% 197
2017
Q3
$1.3M Buy
14,000
+4,000
+40% +$353K 0.06% 198
2017
Q2
$908K Sell
10,000
-11,600
-54% -$1.06M 0.04% 260
2017
Q1
$1.9M Sell
21,600
-12,500
-37% -$1.11M 0.11% 150
2016
Q4
$2.83M Buy
34,100
+2,000
+6% +$172K 0.15% 120
2016
Q3
$2.97M Buy
32,100
+8,000
+33% +$753K 0.14% 127
2016
Q2
$1.88M Buy
24,100
+12,000
+99% +$1.02M 0.13% 152
2016
Q1
$998K Sell
12,100
-15,800
-57% -$1.29M 0.06% 236
2015
Q4
$2.92M Buy
27,900
+27,500
+6,875% +$2.87M 0.17% 121
2015
Q3
$42K Buy
+400
New +$53.4K ﹤0.01% 710

Other funds holding BMRN

CSS LLC's BMRN Position: Q2 2026 in Review

CSS LLC increased its BioMarin Pharmaceuticals (BMRN) stake by 41% in Q2 2026, buying an estimated $362K and bringing the position to 22,580 shares worth $1.29M. The position accounts for 0.05% of the portfolio, ranked #268.

CSS LLC first reported a position in BMRN in Q3 2016 and has held it in 11 quarters since. The position peaked at $1.3M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • CSS LLC held 22,580 shares of BioMarin Pharmaceuticals worth $1.29M as of Q2 2026.
  • CSS LLC bought 6,600 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $362K.
  • BioMarin Pharmaceuticals made up 0.05% of CSS LLC's portfolio in Q2 2026, its #268 holding.
  • CSS LLC first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 11 quarters since.
  • CSS LLC's BioMarin Pharmaceuticals position peaked at $1.3M in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.